Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Wondering what the cosmos has to advice you for your health? Every day the stars align and we catch what messages they for ...

The residential battery energy storage system is the first non-vehicle product by Ola Electric. This new solution will ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock soared 65% Wednesday after the biotech company announced a major asset purchase and license agreement with Novo Nordisk (NYSE:NVO) for its ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.18, along with a high estimate of $52.00 and a low estimate of $18.00. This upward ...

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...